Image Name

Enterprise News

Jiangsu Vcare Launches Phase III Clinical Trial of VC005, a Highly Selective JAK1 Inhibitor, for Ankylosing Spondylitis

Jiangsu Vcare Launches Phase III Clinical Trial of VC005, a Highly Selective JAK1 Inhibitor, for Ankylosing Spondylitis

Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the official initiation of the Phase III clinical trial of VC005 Tablets—a self-developed second-generation highly selective JAK1 inhibitor—for the oral treatment of ankylosing spondylitis (AS). This marks the second Phase III clinical trial of VC005 Tablets, following the one for oral treatment of moderate-to-severe atopic dermatitis (AD), signifying that the AS indication has entered the confirmatory clinical research stage.

Time：2025-09-15 17:19

Jiangsu Vcare Initiates Phase II Clinical Trial of VC005 Tablets, a Second-Generation Highly Selective JAK1 Inhibitor, for Oral Treatment of Vitiligo

Jiangsu Vcare Initiates Phase II Clinical Trial of VC005 Tablets, a Second-Generation Highly Selective JAK1 Inhibitor, for Oral Treatment of Vitiligo

Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) officially initiated the Phase II clinical trial of VC005 Tablets, a second-generation highly selective JAK1 inhibitor independently developed by the company, for a new oral indication – the treatment of non-segmental vitiligo (NSV).

Time：2025-09-12 17:13

Vcare Enters into Exclusive Partnership with Huadong Medicine to Commercialize its second-generation JAK1 inhibitor, VC005 tablets, in China

Vcare Enters into Exclusive Partnership with Huadong Medicine to Commercialize its second-generation JAK1 inhibitor, VC005 tablets, in China

August 8, 2025 – Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced today that it has entered into an exclusive strategic partnership with Huadong Medicine (Hangzhou) Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (000963.SZ, "Huadong Medicine"), for the commercialization rights of Jiangsu Vcare’s innovative product VC005 tablets in mainland China.

Time：2025-08-11 22:05

Jiangsu Vcare Completes Full Patient Enrollment for Phase II Clinical Trial of VC005 Topical Gel in Mild-to-Moderate Atopic Dermatitis

Jiangsu Vcare Completes Full Patient Enrollment for Phase II Clinical Trial of VC005 Topical Gel in Mild-to-Moderate Atopic Dermatitis

Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the completion of full patient enrollment for its Phase II clinical trial of the self-developed, next-generation highly selective JAK1 inhibitor, VC005 topical gel, for the treatment of mild-to-moderate Atopic Dermatitis (AD). This marks a significant milestone in the VC005 gel development program.

Time：2025-07-31 18:28

Breakthrough for Next-Generation TRK Inhibitor: Jiangsu Vcare's New Anti-tumor Drug, Eratrectinib (VC004) Capsules, Receives NDA Acceptance

Breakthrough for Next-Generation TRK Inhibitor: Jiangsu Vcare's New Anti-tumor Drug, Eratrectinib (VC004) Capsules, Receives NDA Acceptance

Recently, the NDA for Eratrectinib (VC004) capsules, a next-generation anti-resistance TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) has been officially accepted by China's NMPA. Previously granted priority review designation, the drug holds promise as a new treatment option for patients with advanced solid tumors.

Time：2025-07-03 17:15

Jiangsu Vcare's Next-Generation TRK Inhibitor Eratrectinib (VC004) Capsules, Have Been Included in Priority Review

Jiangsu Vcare's Next-Generation TRK Inhibitor Eratrectinib (VC004) Capsules, Have Been Included in Priority Review

Recently, Eratrectinib (VC004) capsules, a self-developed next-generation anti-resistant TRK inhibitor by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), were included in the priority review list by the NMPA, through public notice. This milestone positions the drug within the first tier of next-generation anti-resistant products targeting the same mechanism in China.

Time：2025-05-30 17:01

Jiangsu Vcare Completes Enrollment in Phase III Clinical Trial of Antiplatelet Drug Vicagrel in China

Jiangsu Vcare Completes Enrollment in Phase III Clinical Trial of Antiplatelet Drug Vicagrel in China

Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the completion of patient enrollment for its self-developed Class 1 innovative antiplatelet drug, Vicagrel Capsules, in a Phase III clinical trial conducted in China. This study evaluates the efficacy and safety of Vicagrel compared to Clopidogrel in patients with acute coronary syndrome (ACS). The milestone marks a critical step toward Vicagrel’s potential market approval.

Time：2025-05-21 17:03

New Indication Added! Jiangsu Vcare’s Second-Generation Highly Selective JAK1 Inhibitor VC005 Tablets Approved for IND in Oral Treatment of Vitiligo

New Indication Added! Jiangsu Vcare’s Second-Generation Highly Selective JAK1 Inhibitor VC005 Tablets Approved for IND in Oral Treatment of Vitiligo

On May 8, 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) achieved another major milestone in its self-developed second-generation highly selective JAK1 inhibitor, VC005 tablets. The project, intended for the oral treatment of non-segmental vitiligo received official IND approval from the NMPA (Application No.: CXHL2500200).

Time：2025-05-09 17:38

< 1234...10 >
Jiangsu Vcare Pharmaceutical Technology Co., Ltd.

Company Address:

No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China

Subsidiary NJVcare Website：

en.njvcare.com

Jiangsu Vcare Pharmaceutical Technology Co., Ltd.

Scan to see

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.

SEO

Powerby：www.300.cn nanjing.300.cn